Enovis Corporation (ENOV)
NYSE: ENOV · Real-Time Price · USD
33.05
-0.03 (-0.09%)
At close: May 9, 2025, 4:00 PM
33.05
0.00 (0.00%)
After-hours: May 9, 2025, 7:00 PM EDT
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
| Total Prevention & Recovery | 1.10B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Prevention & Recovery Growth | 1.97% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Reconstructive | 1.01B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Reconstructive Growth | 60.16% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Medical Technology | 2.11B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Medical Technology Growth | 23.46% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| U.S. Bracing & Support | 469.32M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| U.S. Bracing & Support Growth | 2.89% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| U.S. Other P&R | 270.74M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| U.S. Other P&R Growth | 0.34% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| International P&R | 357.90M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| International P&R Growth | 2.02% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| U.S. Reconstructive | 505.62M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| U.S. Reconstructive Growth | 18.58% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| International Reconstructive | 504.05M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| International Reconstructive Growth | 147.06% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Capex by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
| Total Medical Technology Capital Expenditures | 180.71M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Medical Technology Capital Expenditures Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Prevention & Recovery Capital Expenditures | 34.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Prevention & Recovery Capital Expenditures Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Reconstructive Capital Expenditures | 146.71M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Reconstructive Capital Expenditures Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EBITDA by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
| Prevention & Recovery Adjusted EBITDA | 159.60M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Prevention & Recovery Adjusted EBITDA Growth | 4.65% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Reconstructive Adjusted EBITDA | 216.92M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Reconstructive Adjusted EBITDA Growth | 85.84% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
| United States | 1.25B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| United States Growth | 8.10% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Foreign Locations | 861.95M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Foreign Locations Growth | 55.35% |
Log In |
Log In |
Log In |
Log In | Upgrade
|